22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
Effective January 1, 2020, employers should be using the revised Form W-4 in the new hire process. ...
Read More >
California Appellate Court Provides Guidance - Passthrough payments negotiated prior to the dissolu...
Read More >
On December 20, President Trump signed the Further Consolidated Appropriations Act, 2020 (the “Act”...
Read More >
Coronavirus disease 2019 (COVID-19) is a respiratory disease caused by a new coronavirus, which has ...
Read More >
California Governor Gavin Newsom has signed AB 5, and the new law will take effect January 1, 2020. ...
Read More >
I’ve been an ERISA attorney for over 20 years and the one opinion I’ve had for that long is that h...
Read More >